Barry John Langham

This inventor holds 26 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 5 EPO patents, primarily in Kinase Inhibitors. Top assignees: Ucb Pharma, S.a., Celltech R&d Limited, John Wyeth Brother, Limited. Active years: 1987-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Barry John Langham. Retrieved from https://idiyas.com/inventor/barry-john-langham

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 2)

% Patents Active = 50.0

CIPO Patents = 2

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 4.5

ph-index = 6

Forward Citations = 113(Granted Patents)

Location History:

Reading, GB (1997 - 2009)
Berkshire, GB (2010 - 2012)
Slough Berkshire, GB (2013)
Slough, GB (1987 - 2015)

Company Filing History:

John Wyeth Brother, Limited

patents

4. 1 out of 81

Celltech Therapeutics Limited

patents

Years Active: 1987-2015

Loading Chart...

Areas of Expertise:

Kinase Inhibitors

Quinoline Derivatives

Thieno-Pyridine Derivatives

Bicyclic Heteroaromatic Compounds

Pyridine Derivatives

Oxopyridine Derivatives

Enamine Derivatives

Squaric Acid Derivatives

Nitrogen Heterocycles

Isoquinolin Derivatives

Thienoquinolizines

Adrenoceptor Compounds

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9029392 - Quinoline derivatives as kinase inhibitors (2015-05-12),

2. 8637491 - Thieno-pyridine derivatives as MEK inhibitors (2014-01-28),

3. 8604051 - Thieno-pyridine derivatives as MEK inhibitors (2013-12-10),

4. 8487101 - Thieno-pyridine derivatives as MEK inhibitors (2013-07-16),

5. 8394822 - Thieno-pyridine derivatives as MEK inhibitors (2013-03-12),

6. 8350037 - Thieno-pyridine derivatives as MEK inhibitors (2013-01-08),

7. 8283359 - Thieno-pyridine derivatives as MEK inhibitors (2012-10-09),

8. 7763729 - Bicyclic heteroaromatic derivatives (2010-07-27),

9. 7592455 - Bicyclic heteroaromatic compounds as kinase inhibitors (2009-09-22),

10. 7521460 - Thienopyridone derivatives as kinase inhibitors (2009-04-21),

11. 7456286 - Bicyclic heteroaromatic compounds as kinase inhibitors (2008-11-25),

12. 7423047 - Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors (2008-09-09),

13. 7323464 - Pyridine and pyrimidine derivatives (2008-01-29),

14. 7176215 - Bicyclic oxopyridine and oxopyrimidine derivatives (2007-02-13),

15. 6780874 - Enamine derivatives (2004-08-24),

Title: Barry John Langham: Pioneering Innovator in Medicinal Chemistry

Introduction:

Barry John Langham, a remarkable inventor based in Reading, GB, has garnered acclaim for his unwavering commitment to innovation and excellence. With an impressive portfolio of 26 patents, Langham is a trailblazer whose work inspires future generations to push boundaries and think innovatively.

Latest Patents:

Langham's latest patents showcase his expertise in medicinal chemistry. One notable invention is the development of quinoline derivatives as kinase inhibitors. These compounds, with a unique fluorinated ethyl side-chain, exhibit selectivity in inhibiting PI3 kinase enzymes, showing promise in treating various medical conditions such as inflammatory, autoimmune, and oncological diseases. Additionally, Langham has pioneered thieno-pyridine derivatives as MEK inhibitors, presenting novel solutions for inflammatory, autoimmune, and oncological disorders.

Career Highlights:

Langham's illustrious career has seen him make significant contributions to companies like UCB Pharma S.A. and Celltech R&D Limited. His innovative spirit and scientific acumen have been instrumental in driving advancements in the pharmaceutical and biotechnology industries, revolutionizing the landscape of medicinal chemistry.

Collaborations:

Throughout his career, Langham has collaborated with renowned professionals in the field, including Daniel Christopher Brookings and Sarah Catherine Archibald. These collaborations have not only enriched Langham's work but have also led to groundbreaking discoveries that have the potential to transform healthcare and improve patient outcomes.

Conclusion:

In conclusion, Barry John Langham stands as a beacon of innovation in the world of medicinal chemistry. His dedication to pushing the boundaries of scientific discovery and his passion for creating impactful solutions underscore his status as a visionary inventor. Langham's remarkable journey serves as a testament to the power of innovation in shaping a better future for all.

Profile summary based on public USPTO records.